What are your top takeaways from ESMO 2023?

Lung Cancer

1. New first line therapy for advanced EGFR Exon 20 NSCLC patients: The PAPILLION trial [Zhou et al., PMID 37870976] was a Phase 3 clinical trial among patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with documented epidermal growth factor receptor (EGFR) ex...

Breast Cancer

1. Pulled analysis of DESTINY BREAST-01, -02 and -03 trials in patients with brain metastases showing intracranial objective response rate of ~45% in patients who received T-DXd compared to the control arm that had objective response rate of ~12-27%.
2. Updated results of monarchE showed con...

Lung Cancer

1. New standard of care: ALINA - pivotal adjuvant study of alectinib for 2 years vs 4 cycles of adjuvant platinum based doublet chemotherapy for patients with resected ALK-positive stage IB-IIIA NSCLC. Whopping 0.24 HR when it comes to DFS benefits, massive CNS DFS benefits, and while OS is...

GU Cancers

1. The EV-302 trial of Enfortumab Vedotin + Pembrolizumab showed remarkable results, with a median OS of over 31 months, more than 65% of patients having RECIST responses, and durable progression free survival for some patients.
   
   
2. The DAD trial was a very interesting Phase I study exploring th...

Breast Cancer

1. The KEYNOTE-756: Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo + Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo + Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer accrued N=1279 patients with ER+/HER2-, grade 3, T1c-T2/cN1-2 or T3-4/cN0-2 patients...

GU Cancers

1. EV-302 trial. EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC). This trial demonstrated major improvements in ov...

GU Cancers

1. EV-302: Establishes EV/Pembro as the new standard of care as frontline treatment for metastatic bladder cancer.
   
   
2. CM-901: Nivolumab + Cis/gem first IO/chemo combo to improve OS relative to Cisplatin-based chemotherapy in frontline patients with metastatic disease.
   
   
3. Double Antibody Drug Conju...

GI Cancers

1. In the PREOPANC-2 study, neoadjuvant chemotherapy with FOLFIRINOX, compared with neoadjuvant gemcitabine-based chemoradiotherapy in patients with borderline resectable/resectable PDAC, did not improve OS. Median OS was 21.9 months in the FFX arm and 21.3 months in the CRT arm (HR 0.87, 9...

GU Cancers

1. EV-302 phase III trial
2. CheckMate 901 phase III trial
3. THOR (cohorts 1 & 2) phase III trial

Hematological Malignancies

Impact of MBL and CHIP on Hematological Malignancies

A large-scale study using the Mayo Clinic Biobank examined the association between monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis of indeterminate potential (CHIP), specifically the L-CHIP and M-CHIP subt...